JNJ-54175446
JNJ-54175446 is an experimental pharmacological agent currently under investigation for its potential therapeutic effects in the treatment of Post-Traumatic Stress Disorder (PTSD) and Alzheimer's disease. It is a potent and selective antagonist of the P2X7 receptor, a protein that plays a significant role in inflammation and cell death.
Mechanism of Action[edit | edit source]
JNJ-54175446 works by blocking the P2X7 receptor. The P2X7 receptor is a type of purinergic receptor for ATP that, when activated, can initiate a series of cellular responses including inflammation and cell death. By inhibiting this receptor, JNJ-54175446 may help to reduce inflammation and protect cells from damage.
Clinical Trials[edit | edit source]
JNJ-54175446 has been tested in several clinical trials for its potential use in treating PTSD and Alzheimer's disease. In a Phase 2 study for PTSD, the drug was found to be well-tolerated and showed promising results in reducing PTSD symptoms. However, further research is needed to confirm these findings and determine the optimal dosing regimen.
In a Phase 1b/2a study for Alzheimer's disease, JNJ-54175446 was found to be safe and well-tolerated. The study also found that the drug was able to reduce levels of a biomarker associated with inflammation in the brain, suggesting that it may have potential as a treatment for Alzheimer's disease.
Potential Side Effects[edit | edit source]
As with any drug, JNJ-54175446 may cause side effects. In clinical trials, the most common side effects reported were headache, dizziness, and nausea. However, these side effects were generally mild and did not lead to discontinuation of the drug.
Future Directions[edit | edit source]
Further research is needed to fully understand the potential benefits and risks of JNJ-54175446. Future studies will likely focus on determining the optimal dosing regimen, further investigating the drug's effects on inflammation and cell death, and exploring its potential use in other conditions associated with P2X7 receptor activation.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
